Market Overview

UPDATE: Goldman Sachs Raises PT to $170 on Regeneron Pharmaceuticals on Eylea EU Approval

Share:
Related REGN
Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff
Stifel Remains Buyers Of Ophthotech As Year-End Binary Event Looms
Clearside Biomedical launches equity offering; shares slip 19% premarket (Seeking Alpha)

Goldman Sachs reiterated its Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and increased its price target from $168 to $170.

Goldman Sachs noted, "FDA approved REGN's Eylea for a new eye disease indication (central retinal vein occlusion, CRVO), in line with our expectation. Eylea was approved last year for the wet AMD indication. We model 2013 US Eylea sales of $1.2bn (62% yoy growth) of which CRVO contributes $104mn."

Regeneron Pharmaceuticals closed at $145.09 on Friday.

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2016BairdDowngradesOutperformNeutral
Jun 2016BernsteinInitiates Coverage onOutperform
Apr 2016Wells FargoDowngradesOutperformMarket Perform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!